Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI (CARB)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Heidi Boyda, Ph.D
- Phone Number: 604-612-5025
- Email: hnboyda@gmail.com
Study Contact Backup
- Name: Delrae Fawcett, MSc
- Phone Number: 6115 604-875-2000
- Email: delrae.fawcett@ubc.ca
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4H4
- Recruiting
- BC Mental Health & Addictions Research Institute
-
Contact:
- Delrae Fawcett, MSc
- Phone Number: 6115 604-875-2000
- Email: delrae.fawcett@ubc.ca
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or female, aged 12+ years for healthy participants or participants with bipolar disorder; or aged 15+ years for participants with non-affective psychosis.
- Recent admission to the Vancouver/Richmond Early Psychosis Intervention (EPI) program related to first episode psychosis or first episode bipolar disorder;
- Participants being treated with an antipsychotic medication principally for psychosis or for bipolar disorder.
- Participants taking aripiprazole must be taking a dose of at least 10mg/day for the duration of the study.
- Participants must have received a minimum of 3 months of continuous antipsychotic drug treatment with either aripiprazole or risperidone principally for psychosis or bipolar disorder;
- Participants may be in- or outpatients.
- Participants able to give informed consent, or informed consent through legally authorized representative.
Exclusion Criteria:
- Total life time exposure to the antipsychotic drug aripiprazole vs risperidone for less than 3 months at time of consent.
- Previously diagnosed with diabetes mellitus, seizure disorders, mental retardation (IQ < 70), or pregnancy (current or within 3 months postpartum)
- Participants who have been treated/are currently being treated with mood stabilizers (paroxetine, lithium, or valproic acid). Prior or concurrent use of Selective Serotonin Reuptake Inhibitor antidepressants (other than paroxetine) is acceptable..
- Received antipsychotic polypharmacy (treatment with more than one antipsychotic drug)
- Participants who are not able to fluently communicate in English.
- Contraindicated for MRI scan (i.e., has had major surgery in the last 6 months, morbid obesity, claustrophobia, and/or has metal in their bodies from a surgical intervention or working in metalwork, or is unsure if metal is present in their bodies, etc.)
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Aripiprazole
Participants receiving treatment of only aripiprazole, as prescribed to them by their psychiatrists, for a minimum of at least 3 continuous months.
|
To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study)
Other Names:
|
|
Risperidone
Participants receiving treatment of only risperidone, as prescribed to them by their psychiatrists, for a minimum of at least 3 continuous months.
|
To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
|
|
Controls
Healthy participants who are not taking any antipsychotic medications.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MRI Brain Scans (Composite Measure)
Time Frame: Day 1 (Visit 1)
|
Using structural MRI, we will measure total brain volume (TBV), grey matter volume (GMV), white matter volumes (WMV), and/or volumes of other brain structures.
|
Day 1 (Visit 1)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Metabolic Fasting Blood Work (Composite Measures)
Time Frame: Day 1 (Visit 1)
|
By obtaining two tubes of fasting blood, we will determine fasting metabolic parameters of common blood components (lipids, cholesterol, leptin, adiponectin, glucose, and insulin).
|
Day 1 (Visit 1)
|
|
Genetic Measures (Composite Measure)
Time Frame: Day 1 (Visit 1)
|
An optional component, as obtained from blood work, will be to determine potential genetic variants in several candidate genes (such as BDNF) that predispose some subjects to changes in brain morphology.
|
Day 1 (Visit 1)
|
|
Neuropsychological Assessments
Time Frame: At time of Day 1 (Only for those taking antipsychotic medications)
|
To assess cognitive functioning for those subject's taking risperidone or aripiprazole, we will administer a set of standard scales and surveys to measure executive and cognitive functioning.
|
At time of Day 1 (Only for those taking antipsychotic medications)
|
|
Psychiatric Assessment
Time Frame: At time of Day 1 (Only for those taking antipsychotic medications)
|
To assess mental health symptoms for those subject's taking risperidone or aripiprazole, we will administer a set of interviews (PANSS and MINI) to assess mental health symptoms.
|
At time of Day 1 (Only for those taking antipsychotic medications)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Alasdair M Barr, Ph.D, University of British Columbia
- Principal Investigator: Lili Kopala, M.D., University of British Columbia
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Bipolar and Related Disorders
- Bipolar Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agonists
- Dopamine Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Aripiprazole
- Risperidone
Other Study ID Numbers
Other Study ID Numbers
- H14-01075
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.